The Company's Board of Director's resolution on
the Company's 2022 Q2 financial statement
Date of events
2022/08/12
To which item it meets
paragraph 31
Statement
1.Date of the board of directors submitted or approved:2022/08/12
2.Date of the audit committee approved:2022/08/12
3.Start and end dates of financial reports or unaudited financial
information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):
2022/01/01~2022/06/30
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):2,471,885
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):917,584
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):621,020
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):622,089
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):419,165
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):419,165
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):6.13
11.Total assets end of the period (thousand NTD):10,247,409
12.Total liabilities end of the period
(thousand NTD):6,298,358
13.Equity attributable to owners of parent end of the
period (thousand NTD):3,372,671
14.Any other matters that need to be specified:NA
Attachments
Original Link
Original Document
Permalink
Disclaimer
Bora Pharmaceuticals Co. Ltd. published this content on 12 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 August 2022 12:14:13 UTC.
Bora Pharmaceuticals Co Ltd is a Taiwan-based company principally engaged in the agency and sales of western medicines, as well as the research, development, manufacture and sales of new drugs and health products. The Company's main products are categorized into prescription drugs and health care products, including central nervous drugs, cardiovascular drugs, antibiotics, antiviral agents, ophthalmic drugs, gastrointestinal drugs, foam ingots and health care products. In addition, the Company has biopharmaceutical technologies related to the development of cell lines for the production of protein drugs, the development and analysis of upstream and downstream processes, as well as the establishment of quality control and testing specifications and the creation of cell banks.